vs
Maplebear Inc.（CART）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Maplebear Inc.的季度营收约是Revvity的1.3倍（$992.0M vs $772.1M），Revvity净利率更高（12.7% vs 8.2%，领先4.6%），Maplebear Inc.同比增速更快（12.3% vs 5.9%），Maplebear Inc.自由现金流更多（$171.0M vs $161.8M），过去两年Maplebear Inc.的营收复合增速更高（10.0% vs 9.0%）
Maplebear Inc. 以Instacart为品牌开展业务，是总部位于美国旧金山的零售媒体及配送企业，在美国和加拿大运营生鲜杂货配送与自提服务。用户可通过官网及移动应用从合作商户订购食品杂货，在法律允许的地区还可选购酒类商品，所有订单由专属采购专员负责拣选、打包并配送上门。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CART vs RVTY — 直观对比
营收规模更大
CART
是对方的1.3倍
$772.1M
营收增速更快
CART
高出6.5%
5.9%
净利率更高
RVTY
高出4.6%
8.2%
自由现金流更多
CART
多$9.2M
$161.8M
两年增速更快
CART
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $992.0M | $772.1M |
| 净利润 | $81.0M | $98.4M |
| 毛利率 | 72.3% | — |
| 营业利润率 | 9.9% | 14.5% |
| 净利率 | 8.2% | 12.7% |
| 营收同比 | 12.3% | 5.9% |
| 净利润同比 | -45.3% | 3.9% |
| 每股收益（稀释后） | $0.31 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CARTRVTY
| Q4 25 | $992.0M | $772.1M | ||
| Q3 25 | $939.0M | $698.9M | ||
| Q2 25 | $914.0M | $720.3M | ||
| Q1 25 | $897.0M | $664.8M | ||
| Q4 24 | $883.0M | $729.4M | ||
| Q3 24 | $852.0M | $684.0M | ||
| Q2 24 | $823.0M | $691.7M | ||
| Q1 24 | $820.0M | $649.9M |
净利润CARTRVTY
| Q4 25 | $81.0M | $98.4M | ||
| Q3 25 | $144.0M | $46.7M | ||
| Q2 25 | $116.0M | $53.9M | ||
| Q1 25 | $106.0M | $42.2M | ||
| Q4 24 | $148.0M | $94.6M | ||
| Q3 24 | $118.0M | $94.4M | ||
| Q2 24 | $61.0M | $55.4M | ||
| Q1 24 | $130.0M | $26.0M |
毛利率CARTRVTY
| Q4 25 | 72.3% | — | ||
| Q3 25 | 73.7% | 53.6% | ||
| Q2 25 | 74.2% | 54.5% | ||
| Q1 25 | 74.8% | 56.5% | ||
| Q4 24 | 75.2% | — | ||
| Q3 24 | 75.2% | 56.3% | ||
| Q2 24 | 75.7% | 55.7% | ||
| Q1 24 | 74.9% | 54.6% |
营业利润率CARTRVTY
| Q4 25 | 9.9% | 14.5% | ||
| Q3 25 | 17.7% | 11.7% | ||
| Q2 25 | 13.6% | 12.6% | ||
| Q1 25 | 12.3% | 10.9% | ||
| Q4 24 | 17.6% | 16.3% | ||
| Q3 24 | 16.2% | 14.3% | ||
| Q2 24 | 6.3% | 12.4% | ||
| Q1 24 | 17.6% | 6.8% |
净利率CARTRVTY
| Q4 25 | 8.2% | 12.7% | ||
| Q3 25 | 15.3% | 6.7% | ||
| Q2 25 | 12.7% | 7.5% | ||
| Q1 25 | 11.8% | 6.4% | ||
| Q4 24 | 16.8% | 13.0% | ||
| Q3 24 | 13.8% | 13.8% | ||
| Q2 24 | 7.4% | 8.0% | ||
| Q1 24 | 15.9% | 4.0% |
每股收益（稀释后）CARTRVTY
| Q4 25 | $0.31 | $0.86 | ||
| Q3 25 | $0.51 | $0.40 | ||
| Q2 25 | $0.41 | $0.46 | ||
| Q1 25 | $0.37 | $0.35 | ||
| Q4 24 | $0.53 | $0.77 | ||
| Q3 24 | $0.42 | $0.77 | ||
| Q2 24 | $0.20 | $0.45 | ||
| Q1 24 | $0.43 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $687.0M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.5B | $7.3B |
| 总资产 | $3.7B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CARTRVTY
| Q4 25 | $687.0M | $919.9M | ||
| Q3 25 | $1.7B | $931.4M | ||
| Q2 25 | $1.6B | $991.8M | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.4B | $1.2B | ||
| Q3 24 | $1.3B | $1.2B | ||
| Q2 24 | $1.4B | $2.0B | ||
| Q1 24 | $1.5B | $1.7B |
股东权益CARTRVTY
| Q4 25 | $2.5B | $7.3B | ||
| Q3 25 | $3.5B | $7.4B | ||
| Q2 25 | $3.3B | $7.6B | ||
| Q1 25 | $3.2B | $7.6B | ||
| Q4 24 | $3.1B | $7.7B | ||
| Q3 24 | $2.9B | $7.9B | ||
| Q2 24 | $3.0B | $7.9B | ||
| Q1 24 | $3.1B | $7.8B |
总资产CARTRVTY
| Q4 25 | $3.7B | $12.2B | ||
| Q3 25 | $4.5B | $12.1B | ||
| Q2 25 | $4.4B | $12.4B | ||
| Q1 25 | $4.3B | $12.4B | ||
| Q4 24 | $4.1B | $12.4B | ||
| Q3 24 | $3.9B | $12.8B | ||
| Q2 24 | $4.0B | $13.4B | ||
| Q1 24 | $4.1B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $183.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $171.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 17.2% | 21.0% |
| 资本支出强度资本支出/营收 | 1.2% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.26× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $910.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CARTRVTY
| Q4 25 | $183.0M | $182.0M | ||
| Q3 25 | $287.0M | $138.5M | ||
| Q2 25 | $203.0M | $134.3M | ||
| Q1 25 | $298.0M | $128.2M | ||
| Q4 24 | $153.0M | $174.2M | ||
| Q3 24 | $185.0M | $147.9M | ||
| Q2 24 | $244.0M | $158.6M | ||
| Q1 24 | $105.0M | $147.6M |
自由现金流CARTRVTY
| Q4 25 | $171.0M | $161.8M | ||
| Q3 25 | $272.0M | $120.0M | ||
| Q2 25 | $187.0M | $115.5M | ||
| Q1 25 | $280.0M | $112.2M | ||
| Q4 24 | $141.0M | $149.8M | ||
| Q3 24 | $171.0M | $125.6M | ||
| Q2 24 | $220.0M | $136.6M | ||
| Q1 24 | $91.0M | $129.7M |
自由现金流率CARTRVTY
| Q4 25 | 17.2% | 21.0% | ||
| Q3 25 | 29.0% | 17.2% | ||
| Q2 25 | 20.5% | 16.0% | ||
| Q1 25 | 31.2% | 16.9% | ||
| Q4 24 | 16.0% | 20.5% | ||
| Q3 24 | 20.1% | 18.4% | ||
| Q2 24 | 26.7% | 19.7% | ||
| Q1 24 | 11.1% | 20.0% |
资本支出强度CARTRVTY
| Q4 25 | 1.2% | 2.6% | ||
| Q3 25 | 1.6% | 2.6% | ||
| Q2 25 | 1.8% | 2.6% | ||
| Q1 25 | 2.0% | 2.4% | ||
| Q4 24 | 1.4% | 3.4% | ||
| Q3 24 | 1.6% | 3.3% | ||
| Q2 24 | 2.9% | 3.2% | ||
| Q1 24 | 1.7% | 2.7% |
现金转化率CARTRVTY
| Q4 25 | 2.26× | 1.85× | ||
| Q3 25 | 1.99× | 2.97× | ||
| Q2 25 | 1.75× | 2.49× | ||
| Q1 25 | 2.81× | 3.03× | ||
| Q4 24 | 1.03× | 1.84× | ||
| Q3 24 | 1.57× | 1.57× | ||
| Q2 24 | 4.00× | 2.87× | ||
| Q1 24 | 0.81× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CART
| Transaction | $698.0M | 70% |
| Advertising And Other | $294.0M | 30% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
